News
Gedea Biotech Announces CE-Marking for pHyph: A Novel Antibiotic-Free Treatment for Bacterial Vaginosis
Gedea Biotech Announces CE-Marking for pHyph: A Novel Antibiotic-Free Treatment for Bacterial Vaginosis
PRESS RELEASE Gedea Biotech Receives US Patent for Preventing Preterm Birth
Gedea Biotech announced today that the United States Patent and Trademark Office (USPTO) has granted the company’s…
Closing the Health Gap
On the Iternational Women's Day we want to address the THE WOMEN’S HEALTH GAP
Gedea wins prestigious scale up award
On Thursday November 28th, at the Nordic Mentor Network For Entrepreneurship - NOME annual meeting in Copenhagen, we…
Emilia, industrial doctoral student at Gedea and Karolinska Institutet
Emilia Lahtinen is an industrial Ph.D. student at Gedea and at Karolinska Institutet. Her project has the title…
Anna-Karin Areskog strengthens the team
Gedea has recently strengthened its team by hiring Anna-Karin Areskog as QA Director. Anna-Karin has been a consultant…
Gedea´s share issue oversubscribed by 54%
Gedea Biotech AB carried out a rights issue of SEK 24.3 million during October. The interest from both existing owners…
Per-Ola Forsberg new CFO at Gedea
We are pleased to announce that Per-Ola Forsberg has been appointed as the new CFO of Gedea since April 20th. Per-Ola…
Convincing efficacy and safety results
pHyph shows convincing symptom relief and longterm effect. Already at first day of treatment many patients see a relief in symptoms and at day 7 nearly 70% report absence of symptoms. When treated, the patients stay well and after 35 days, 100% of patients are still free from BV, compared to 54-77% with antibiotics.
90% Symptom reduction
In our most recent and largest clinical trial so far, symptom reduction was seen in 90% of patients.
Day 7
By day 7, nearly 70% of patients were free of symptoms.
Day 35
100% are still free from BV
The CE-mark confirms the efficacy and safety of our product, and opens up a large market opportunity in Europe. The novel, antibiotic free mode of action will improve treatment of bacterial vaginosis for millions of women and reduce use of antibiotics, and our ambition is to make pHyph available in pharmacies in the first markets in 2026
Annette Säfholm, CEO
annette.safholm@gedeabiotech.com
+46 (0) 708 - 91 86 81
According to the World Health Organization (WHO), antibiotic resistance is one of the greatest threats to global health of our time. A total of 2,3% of all antibiotics prescribed to women in Sweden are used to treat bacterial vaginosis.*
*) Socialstyrelsen’s (the Swedish National Board of Health and Welfare) pharmaceutical database 2024